FEBRUARY 16 2022 17:15 (CET)

Webinar:

COV-BOOST: Safety and immunogenicity of 7 COVID-19 vaccines as a 3rd dose (booster) following ChAdOx1 nCov-19 or BNT162b2 in the UK

With Prof. Saul N. Faust, NIHR Southampton Clinical Research Facility and Biomedical Research Centre

Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, the reactogenicity and immunogenicity of seven different COVID-19 vaccines as a third dose after two doses of ChAdOx1 nCov-19 (ChAd, Oxford-AstraZeneca) or BNT162b2 (BNT, Pfizer-BioNtech) were investigated. Participants were aged 30 years and older, and were at least 70 days post two doses of ChAd or at least 84 days post two doses of BNT primary COVID-19 immunisation course, with no history of laboratory-confirmed SARS-CoV-2 infection.

In the webinar, Prof. Faust will present the details of the study set up and explain the results and derived recommendations.

VACCELERATE, the EU funded clinical research network for the coordination & conduct of COVID-19 vaccine trials is looking forward to hosting this webinar.

The webinar will be recorded and published on https://vaccelerate.eu/.

In cooperation with